FDA Approves Groundbreaking Hair Loss Drug for Adolescents and Adults
TL;DR Summary
The FDA has approved LITFULO, a hair loss drug, to treat alopecia areata, an autoimmune disease that causes hair loss on the scalp, face, and body. The drug is approved for adults and adolescents aged 12 and over with severe alopecia areata. The drug inhibits two types of enzymes, blocking inflammatory signaling and cell-killing activity from T cells, which have been implicated in the development of alopecia areata. The clinical trial showed a statistically significant increase in hair coverage for those taking 50 mg of LITFULO compared to placebo.
- New Hair Loss Drug Approved by FDA Technology Networks
- Pfizer's Litfulo boasts an alopecia edge over Lilly's Olumiant FiercePharma
- Pfizer’s Litfulo approved by FDA as first treatment for adolescents with severe alopecia areata PMLiVE
- FDA Approves Ritlecitinib for Alopecia Areata for Adolescents, Adults Drug Topics
- FDA Approves First Drug for Adolescent Hair Loss Newsmax
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 4 min read
Condensed
88%
736 → 89 words
Want the full story? Read the original article
Read on Technology Networks